GINA GUILLOTTE: Open Payments
NPI 1063163012 · PASCAGOULA, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,493 in 132 payments from 39 companies in 2025. Trend: 2023 $1,157 · 2024 $1,202 · 2025 $3,493
Food & beverage: $3,493
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $522 |
| E.R. Squibb & Sons, L.L.C. | 17 | $336 |
| Janssen Biotech, Inc. | 14 | $253 |
| Incyte Corporation | 5 | $217 |
| BeOne Medicines USA, Inc. | 5 | $193 |
| Merck Sharp & Dohme LLC | 9 | $163 |
| Novartis Pharmaceuticals Corporation | 8 | $156 |
| Genentech, Inc. | 1 | $144 |
| Geron Corporation | 2 | $136 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $130 |
Products named: REBLOZYL, OPDIVO, KEYTRUDA, Itovebi, RYTELO, LYNPARZA, Nubeqa, Zynyz.
Industry payments across MS — which companies pay providers there.
